News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 4, 2019
-
Jan 7, 2019Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets
-
Nov 5, 2018Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease
-
Apr 26, 2018First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor
-
Jan 11, 2018FDA has granted IND approval for Immunic’s oral investigational drug IMU-838
-
Dec 12, 2017Two phase 1 studies for IMU-838 in healthy volunteers have been completed